Abstract
Original language | English |
---|---|
Pages (from-to) | 225-235.e10 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 9 |
Issue number | 1 |
Early online date | 2020 |
DOIs | |
Publication status | Published - Jan 2021 |
Keywords
- Allergen components
- EuroPrevall
- Europe
- IgE sensitization
- Prediction
- Severity
- Walnut allergy
- iFAAM
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, No. 1, 01.2021, p. 225-235.e10.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Walnut Allergy Across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity
AU - Lyons, Sarah A.
AU - Datema, Mareen R.
AU - le, Thuy-My
AU - Asero, Riccardo
AU - Barreales, Laura
AU - Belohlavkova, Simona
AU - de Blay, Frédéric
AU - Clausen, Michael
AU - Dubakiene, Ruta
AU - Fernández-Perez, Cristina
AU - Fritsche, Philipp
AU - Gislason, David
AU - Hoffmann-Sommergruber, Karin
AU - Jedrzejczak-Czechowicz, Monika
AU - Jongejan, Laurian
AU - Kowalski, Marek L.
AU - Kralimarkova, Tanya Z.
AU - Lidholm, Jonas
AU - Papadopoulos, Nikolaos G.
AU - Pontoppidan, Bo
AU - Popov, Todor A.
AU - Prado, Nayade del
AU - Purohit, Ashok
AU - Reig, Isabel
AU - Seneviratne, Suranjith L.
AU - Sinaniotis, Athanasios
AU - Vassilopoulou, Emilia
AU - Versteeg, Serge A.
AU - Vieths, Stefan
AU - Zwinderman, Aeilko H.
AU - Welsing, Paco M. J.
AU - Mills, E. N. Clare
AU - Ballmer-Weber, Barbara K.
AU - Knulst, André C.
AU - Fernández-Rivas, Montserrat
AU - van Ree, Ronald
N1 - Funding Information: We thank all the patients for their participation in the study. We thank ALK Abello (Madrid, Spain) for their generous gift of SPT reagents. We acknowledge the support by the 6th and 7th Framework Programmes of the European Union , for EuroPrevall (FP6-FOOD-CT-2005-514000) and iFAAM (grant agreement no. 312147), respectively. Funding Information: This work was funded by the European Commission under the 6th Framework Programme through EuroPrevall (FP6-FOOD-CT-2005-514000), and the 7th Framework Programme iFAAM (grant agreement no. 31214).Conflicts of interest: All authors declare grants from the European University through EuroPrevall (FP6-FOOD-CT-2005-514000) and iFAAM (grant agreement no. 31214) during the conduct of the study. Outside of submitted work: F. De Blay reports personal fees from Aimmune; grants from Stallerg?nes Greer, Chiesi, Mundipharma, Novartis, and Regeneron; and board membership for DVB, Stallerg?nes Greer, Novartis, ALK, Mundipharma, Boehringer, AstraZeneca, Medapharma, and Boston Scientific. J. Lidholm and B. Pontoppidan are employees of ThermoFisher Scientific. N. G. Papadopoulos reports personal fees from Novartis, Nutricia, HAL Allergy, Menarini/Faes Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GlaxoSmithKline (GSK), MSD, ASIT Biotech, and Boehringer Ingelheim and grants from Gerolymatos International SA and Capricare. S. Vieths reports personal fees from ?rzteverband Deutscher Allergologen, Swiss Society for Allergy and Immunology, Schattauer Allergologie Handbuch, Elsevier Nahrungsmittelallergien und Intoleranzen, Karger Food Allergy: Molecular Basis and Clinical Practice, and Pharmacon and nonfinancial support from German Research Foundation, European Directorate for the Quality of Medicines and Health Care, European Academy of Allergy and Clinical Immunology, German Chemical Society (GDCh), AKM Allergiekongress, International Union of Immunological Societies, and Spanish Society for Allergy and Clinical Immunology. E.N.C. Mills reports grants from Reacta Biotech and is shareholder of Reacta Biotech Ltd. B. Ballmer-Weber reports personal fees from ThermoFisher Scientific. M. Fern?ndez-Rivas reports grants and personal fees from Aimmune Therapeutics and Diater and personal fees from DBV, Allergy Therapeutics, GSK, HAL Allergy, Novartis, ThermoFisher Scientific, and SPRIM. R. Van Ree reports personal fees from HAL Allergy BV, Citeq BV, Angany In., and ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.We thank all the patients for their participation in the study. We thank ALK Abello (Madrid, Spain) for their generous gift of SPT reagents. We acknowledge the support by the 6th and 7th Framework Programmes of the European Union, for EuroPrevall (FP6-FOOD-CT-2005-514000) and iFAAM (grant agreement no. 312147), respectively. Funding Information: This work was funded by the European Commission under the 6th Framework Programme through EuroPrevall (FP6-FOOD-CT-2005-514000), and the 7 th Framework Programme iFAAM (grant agreement no. 31214). Funding Information: Conflicts of interest: All authors declare grants from the European University through EuroPrevall (FP6-FOOD-CT-2005-514000) and iFAAM (grant agreement no. 31214) during the conduct of the study. Outside of submitted work: F. De Blay reports personal fees from Aimmune; grants from Stallergènes Greer , Chiesi , Mundipharma , Novartis , and Regeneron ; and board membership for DVB, Stallergènes Greer, Novartis, ALK, Mundipharma, Boehringer, AstraZeneca, Medapharma, and Boston Scientific. J. Lidholm and B. Pontoppidan are employees of ThermoFisher Scientific. N. G. Papadopoulos reports personal fees from Novartis, Nutricia, HAL Allergy, Menarini/Faes Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GlaxoSmithKline (GSK), MSD, ASIT Biotech, and Boehringer Ingelheim and grants from Gerolymatos International SA and Capricare . S. Vieths reports personal fees from Ärzteverband Deutscher Allergologen, Swiss Society for Allergy and Immunology, Schattauer Allergologie Handbuch, Elsevier Nahrungsmittelallergien und Intoleranzen, Karger Food Allergy: Molecular Basis and Clinical Practice, and Pharmacon and nonfinancial support from German Research Foundation , European Directorate for the Quality of Medicines and Health Care , European Academy of Allergy and Clinical Immunology , German Chemical Society (GDCh), AKM Allergiekongress , International Union of Immunological Societies , and Spanish Society for Allergy and Clinical Immunology . E.N.C. Mills reports grants from Reacta Biotech and is shareholder of Reacta Biotech Ltd. B. Ballmer-Weber reports personal fees from ThermoFisher Scientific. M. Fernández-Rivas reports grants and personal fees from Aimmune Therapeutics and Diater and personal fees from DBV, Allergy Therapeutics, GSK, HAL Allergy, Novartis, ThermoFisher Scientific, and SPRIM. R. Van Ree reports personal fees from HAL Allergy BV, Citeq BV, Angany In., and ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Background: Walnut allergy is common across the globe, but data on the involvement of individual walnut components are scarce. Objectives: To identify geographical differences in walnut component sensitization across Europe, explore cosensitization and cross-reactivity, and assess associations of clinical and serological determinants with severity of walnut allergy. Methods: As part of the EuroPrevall outpatient surveys in 12 European cities, standardized clinical evaluation was conducted in 531 individuals reporting symptoms to walnut, with sensitization to all known walnut components assessed in 202 subjects. Multivariable Lasso regression was applied to investigate predictors for walnut allergy severity. Results: Birch-pollen–related walnut sensitization (Jug r 5) dominated in Northern and Central Europe and lipid transfer protein sensitization (Jug r 3) in Southern Europe. Profilin sensitization (Jug r 7) was prominent throughout Europe. Sensitization to storage proteins (Jug r 1, 2, 4, and 6) was detected in up to 10% of subjects. The walnut components that showed strong correlations with pollen and other foods differed between centers. The combination of determinants best predicting walnut allergy severity were symptoms upon skin contact with walnut, atopic dermatitis (ever), family history of atopic disease, mugwort pollen allergy, sensitization to cat or dog, positive skin prick test result to walnut, and IgE to Jug r 1, 5, 7, or carbohydrate determinants (area under the curve = 0.81; 95% CI, 0.73-0.89). Conclusions: Walnut-allergic subjects across Europe show clear geographical differences in walnut component sensitization and cosensitization patterns. A predictive model combining results from component-based serology testing with results from extract-based testing and information on clinical background allows for good discrimination between mild to moderate and severe walnut allergy.
AB - Background: Walnut allergy is common across the globe, but data on the involvement of individual walnut components are scarce. Objectives: To identify geographical differences in walnut component sensitization across Europe, explore cosensitization and cross-reactivity, and assess associations of clinical and serological determinants with severity of walnut allergy. Methods: As part of the EuroPrevall outpatient surveys in 12 European cities, standardized clinical evaluation was conducted in 531 individuals reporting symptoms to walnut, with sensitization to all known walnut components assessed in 202 subjects. Multivariable Lasso regression was applied to investigate predictors for walnut allergy severity. Results: Birch-pollen–related walnut sensitization (Jug r 5) dominated in Northern and Central Europe and lipid transfer protein sensitization (Jug r 3) in Southern Europe. Profilin sensitization (Jug r 7) was prominent throughout Europe. Sensitization to storage proteins (Jug r 1, 2, 4, and 6) was detected in up to 10% of subjects. The walnut components that showed strong correlations with pollen and other foods differed between centers. The combination of determinants best predicting walnut allergy severity were symptoms upon skin contact with walnut, atopic dermatitis (ever), family history of atopic disease, mugwort pollen allergy, sensitization to cat or dog, positive skin prick test result to walnut, and IgE to Jug r 1, 5, 7, or carbohydrate determinants (area under the curve = 0.81; 95% CI, 0.73-0.89). Conclusions: Walnut-allergic subjects across Europe show clear geographical differences in walnut component sensitization and cosensitization patterns. A predictive model combining results from component-based serology testing with results from extract-based testing and information on clinical background allows for good discrimination between mild to moderate and severe walnut allergy.
KW - Allergen components
KW - EuroPrevall
KW - Europe
KW - IgE sensitization
KW - Prediction
KW - Severity
KW - Walnut allergy
KW - iFAAM
UR - http://www.scopus.com/inward/record.url?scp=85092014969&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaip.2020.08.051
DO - https://doi.org/10.1016/j.jaip.2020.08.051
M3 - Article
C2 - 32916320
SN - 2213-2198
VL - 9
SP - 225-235.e10
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -